ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Since the degraders contain the dasatinib moiety, they also inhibit BCR-ABL kinase activity, which complicates our understanding of the impact of BCR-ABL degradation by degraders in CML growth inhibition.